Clinical trials: Non-valvular Atrial Fibrillation
Atrial Fibrillation
Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation
The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and…
- Trial name
- XaMINA (NCT03284762)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 1,216 people
- Sponsor
- Bayer
Atrial Fibrillation
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) to gain insight into the safety…
- Trial name
- NCT03247569
- Testing
- Edoxaban
- Where
- 6 sites in Thailand
- Volunteers
- 300 people
- Sponsor
- Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company
Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)
Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
It is a multi-center randomized clinical trial (RCT) which will enroll 3746 patients with acute coronary syndrome (ACS) concomitant non-valvular atrial fibrillation (NVAF) and undergoing new generation drug eluting stent (DES)…
- Trial name
- NCT03234114
- Testing
- Triple antithrombotic therapy, Dual antithrombotc therapy-1, Dual antithrombotc therapy-2
- Where
- China
- Volunteers
- 3,746 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-valvular Atrial Fibrillation
Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial Appendage Closure Technology
The aim of the registry is to evaluate Chinese real-World clinical outcomes in patients With AF using the WATCHMAN left Atrial appendage closure technology
- Trial name
- RECORD (NCT03917563)
- Testing
- WATCHMAN LAA occluder
- Where
- China
- Volunteers
- 1,050 people
- Sponsor
- Xijing Hospital
Non-valvular Atrial Fibrillation (NVAF)
FIM Study of the LAmbre™ II LAA Occluder in Non-Valvular AF Patients
To evaluate the preliminary safety and feasibility of the LAmbreTM II Left Atrial Appendage Occluder and the Occluder Delivery System in patients with non-valvular atrial fibrillation who are at increased risk for stroke and…
- Trial name
- NCT07385599
- Testing
- LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Atrial Fibrillation
Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
The study is a prospective, non-randomized, multi-center investigation to establish the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device for subjects with non-valvular atrial fibrillation who are…
- Trial name
- PINNACLE FLX (NCT02702271)
- Testing
- WATCHMAN FLX
- Where
- 29 sites in United States
- Volunteers
- 458 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation
A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin
The primary objective was to evaluate the safety of dabigatran etexilate(BIBR 1048) administered orally at doses of 110 and 150 mg, twice daily, for 12 weeks in patients with non-valvular atrial fibrillation (paroxysmal…
- Trial name
- NCT01136408
- Testing
- Dabigatran etexilate, Warfarin
- Where
- 28 sites in Japan
- Volunteers
- 174 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF
The study is a pilot analysis using a decision on the risk and benefits of oral anticoagulation for stroke reduction for patients with non-valvular atrial fibrillation.
- Trial name
- NCT04956978
- Testing
- Patient Decision Support Tool
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Duke University
Atrial Fibrillation, Anticoagulant-induced Bleeding
Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)
The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Italy for NVAF patients.
- Trial name
- MAS (NCT03803579)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Arianna Anticoagulazione Foundation
Atrial Fibrillation
Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting
- Trial name
- RIVA-F (NCT02690155)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
- Where
- United States
- Volunteers
- 38,831 people
- Sponsor
- Bayer
Patient Compliance, Patient Adherence
Motivational Interviewing to Support Oral AntiCoagulation Adherence in Patients With Non-valvular Atrial Fibrillation (MISOAC-AF)
The purpose of the study is to investigate the impact of motivational interviewing in the adherence of patients with AF to oral anticoagulation (OAC) regimens.
- Trial name
- MISOAC-AF (NCT02941978)
- Testing
- Motivational interview, Control
- Where
- Greece
- Volunteers
- 1,140 people
- Sponsor
- AHEPA University Hospital
Stroke
AMPLATZER™ Amulet™ LAA Occluder Trial
The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN® left atrial appendage closure device in patients with non-valvular atrial…
- Trial name
- Amulet IDE (NCT02879448)
- Testing
- Amulet Left Atrial Appendage Occluder, WATCHMAN Left Atrial Appendage Closure
- Where
- 115 sites in United States, Australia and 9 more
- Volunteers
- 1,878 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation
The primary objective of this study is to compare the incidence of hemorrhagic events in patients treated for non-valvular atrial fibrillation with DU-176b at each dose level versus warfarin potassium (warfarin).
- Trial name
- NCT00829933
- Testing
- DU-176b tablets, Warfarin potassium tablets
- Where
- Japan
- Volunteers
- 536 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atrial Fibrillation
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF…
- Trial name
- HELIOS-AF (NCT05038228)
- Testing
- Apixaban, Rivaroxaban, Dabigatran
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Atrial Fibrillation, Left Atrial Appendage Occlusion
RCT of Minimalist vs Standard Procedure for LAAC in NVAF Patients
Percutaneous left atrial appendage closure (LAAC) is an effective strategy for stroke prevention in patients with non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Occlusion, General Anesthesia, Local Anesthesia
- Trial name
- NCT06969118
- Testing
- Minimalism Transcatheter LAAC Group, Standard Transcatheter LAAC Group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Zhongshan Hospital
Ischemic Stroke, Atrial Fibrillation Non-Rheumatic
STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study
Catheter ablation (CA) has been reported to reduce risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) in retrospective studies, but risk and benefit of CA has not been well elucidated in NVAF with recent…
- Trial name
- STABLED (NCT03777631)
- Testing
- Catheter ablation
- Where
- 46 sites in Japan
- Volunteers
- 251 people
- Sponsor
- Nippon Medical School
Atrial Fibrillation
Safety and Effectiveness of Low Dose Edoxaban in Patients With NVAF
The efficacy and safety of edoxaban has not been adequately studied in Asians versus non-Asians, who are quite different physiologically from each other.
- Trial name
- LEDIOS (NCT03554837)
- Where
- South Korea
- Volunteers
- 2,562 people
- Sponsor
- Samsung Medical Center
Atrial Fibrillation
Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
- Trial name
- DABI-F (NCT02687867)
- Testing
- Dabigatran (Pradaxa), Vitamin K antagonist
- Where
- United States
- Volunteers
- 56,039 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation, Elderly, Frailty, Thrombosis
The Impact of Frailty on Thrombosis of Elderly Patients With NVAF （FTE-NVAF）
This study aims to investigate the use of anticoagulants in elderly patients with non-valvular atrial fibrillation (NVAF) and the incidence of frailty in elderly patients with NVAF.
- Trial name
- NCT04476147
- Testing
- Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Friendship Hospital
Atrial Fibrillation
SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
This is a prospective, non-interventional, open-label, multi-centre study. It will provide additional safety information of Pradaxa in Korean patients with non-valvular AF in clinical settings.
- Trial name
- NCT01774370
- Testing
- Pradaxa (Dabigatran etexilate mesilate)
- Where
- South Korea
- Volunteers
- 3,182 people
- Sponsor
- Boehringer Ingelheim